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ABSTRACT: The in vivo analytical performance of percuta-
neously implanted nitric oxide (NO)-releasing amperometric
glucose biosensors was evaluated in swine for 10 d. Needle-
type glucose biosensors were functionalized with NO-releasing
polyurethane coatings designed to release similar total amounts
of NO (3.1 μmol cm−2) for rapid (16.0 ± 4.4 h) or slower
(>74.6 ± 16.6 h) durations and remain functional as outer
glucose sensor membranes. Relative to controls, NO-releasing
sensors were characterized with improved numerical accuracy
on days 1 and 3. Furthermore, the clinical accuracy and
sensitivity of rapid NO-releasing sensors were superior to
control and slower NO-releasing sensors at both 1 and 3 d
implantation. In contrast, the slower, extended, NO-releasing sensors were characterized by shorter sensor lag times (<4.2 min)
in response to intravenous glucose tolerance tests versus burst NO-releasing and control sensors (>5.8 min) at 3, 7, and 10 d.
Collectively, these results highlight the potential for NO release to enhance the analytical utility of in vivo glucose biosensors.
Initial results also suggest that this analytical performance benefit is dependent on the NO-release duration.
Despite the obvious benefits of continuous glucosemonitoring (CGM) for the management of diabetes,
the utility of in vivo amperometric glucose biosensors is limited
to <1 week due to poor analytical performance, resulting
primarily from the foreign body response (FBR).1,2 Insertion of
the sensor damages vascularized tissue and results in a cascade
of inflammatory events, many of which negatively impact
glucose measurements.3 For example, the resulting passive
adsorption of biomolecules (mainly <15 kDa protein frag-
ments) to the sensor surface initiates an inflammatory response
and is responsible for a dramatic decrease in sensor sensitivity
(∼50%) following sensor implantation.3−6 Increased metabolic
activity of inflammatory cells (i.e., macrophages and foreign
body giant cells) at the sensor−tissue interface results in
inordinate consumption of glucose and oxygen, decreasing their
local concentrations and attenuating sensor performance.7 The
hallmark of the FBR is the formation of a thick, avascular
collagen capsule surrounding the sensor, isolating it from the
tissue and obstructing mass transport of interstitial glucose to
the sensor.3 Indeed, the FBR increases sensor response time,
decreases sensitivity, and often results in device failure.
Efforts to improve the analytical performance of in vivo
biosensors have largely focused on chemical or physical
modifications to the outermost, tissue-contacting membrane
to mitigate the FBR.8 Examples of such strategies include
biomimicry (e.g., the attachment of phospholipids to coating
surfaces),9 employing naturally derived materials as coatings,10
utilizing membranes that reduce cell adhesion,11 encouraging
tissue ingrowth into porous coatings,12−14 and modulating cell
behavior through coating topography.15 The active release of
anti-inflammatory or pro-angiogenic bioactive agents such as
dexamethasone (DX) and vascular endothelial growth factor
(VEGF) has also been proposed as a viable option for
improving glucose sensor function.16,17 However, in addition to
the immune suppression associated with DX18 and pro-
inflammatory roles of VEGF,19 the controlled release of these
molecules from sensor coatings remains a major hurdle.
The controlled release of nitric oxide (NO), an endogenous
molecule with multiple roles in inflammation, wound healing,
and angiogenesis, from polymeric coatings has been shown to
minimize the FBR.1,20−22 Hetrick et al. examined the FBR to
subcutaneously implanted NO-releasing xerogels coated on
silicone elastomers in a murine model.23 Nitric oxide-releasing
implants, which generated ∼1.35 μmol cm−2 NO over 72 h at
fluxes >1 pmol cm−2 s−1, elicited only a mild FBR with reduced
fibrous encapsulation (>25%) after 3 and 6 weeks compared to
tissue near control implants. Concomitant with a reduced FBR,
blood vessel density in the tissue surrounding the NO-releasing
implants was greater (∼50%) than that observed surrounding
control implants. Nichols et al. assessed glucose recovery as a
function of NO release using percutaneously implanted
microdialysis probes.24 A constant NO flux (162 pmol cm−2
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s−1, 4.6 μmol cm−2 NO daily) was achieved from microdialysis
probes by using a saturated NO solution as the perfusate. While
the glucose recovery of control probes was severely diminished
beyond 7 d, NO-releasing microdialysis probes exhibited near
constant glucose recovery throughout the study. These results
were correlated to tissue histology observations. Indeed,
histological analysis of the tissue surrounding NO-releasing
probes at 14 d revealed lower inflammatory cell counts and a
thinner collagen capsule versus probes that did not release NO.
The lessened FBR and increased glucose recovery suggest that
NO release lowered tissue impedance to glucose transport. In a
separate study, Nichols and co-workers investigated the effects
of NO-release kinetics on the FBR to subcutaneous NO-
releasing wire implants (i.e., mock glucose sensors) in a porcine
model.25 Decreased collagen capsule thickness (>50%) was
observed for substrates that released NO for extended
durations (i.e., >14 d) versus wires that did not release NO.
In contrast, substrates with shorter NO-release durations (12−
24 h) were characterized by greater collagen density at the
implant−tissue interface compared to the materials which
released NO for extended durations. Collectively, this body of
work highlights the dramatic effect of NO-release kinetics on
the FBR and the potential to impact the analytical performance
of in vivo glucose biosensors.
Despite extensive characterization of the host response to
NO-releasing implants, the interplay between reduced FBR and
actual sensor performance remains a critical void. To date, only
one study has evaluated the in vivo performance of a NO-
releasing glucose sensor. Gifford et al. reported improved
clinical accuracy for NO-releasing needle-type glucose bio-
sensors implanted in rats for 3 d.26 However, the NO release
from the sensors was limited to 16 h and deterioration of
sensor performance by day 3 was observed.27 Histological
analysis of the surrounding tissues revealed suppressed
inflammation at NO-releasing sensors on day 1 versus controls,
but no benefits following depletion of the NO reservoir.
Clearly, the role of NO release on sensor analytical perform-
ance should be studied in greater detail.
As the severity of the FBR to NO-releasing implants is
dependent on release kinetics, we sought to investigate these
effects on the performance of percutaneously implanted glucose
biosensors. Given previous findings, it is hypothesized that by
extending NO-release duration, sensor merits (i.e., accuracy,
sensitivity, response time) may be maintained for longer
implantation periods (>7 d). Herein, we report on the
analytical performance of NO-releasing needle-type glucose
biosensors in swine as a function of NO-release duration.
■ EXPERIMENTAL SECTION
Materials. Glucose oxidase (GOx; type VII from Aspergillus
niger, >100,000 units g−1), D-(+)-glucose anhydrous, acetami-
nophen (AP), L-ascorbic acid (AA), urea (UA), phenol,
diethylenetriaminepentaacetic acid (DTPA) and sodium
methoxide (5.4 M in methanol) were purchased from Sigma
(St. Louis, MO). Tetrahydrofuran (THF), ethanol (EtOH),
aqueous ammonium hydroxide (30 wt %), and all salts were
purchased from Fisher Scientific (St. Louis, MO), Tetraethyl
orthosilicate (TEOS), (3-mercaptopropyl)trimethoxysilane
(MPTMS), and (3-methylaminopropyl)trimethoxysilane
(MAP3) were purchased from Gelest (Tullytown, PA).
Methyltrimethoxysilane (MTMOS) was purchased from
Fluka (Buchs, Switzerland). Cetyltrimethylammonium bromide
(CTAB) was purchased from Acros Organics (Geel, Belgium).
Hydrothane (AL25-80A) polyurethane (HPU) was a gift from
AdvanSource Biomaterials (Wilmington, MA). Tecoflex (SG-
85A) polyurethane (TPU) was a gift from Lubrizol (Cleveland,
OH). Steel wire (356 μm diam) was purchased from
McMaster-Carr (Atlanta, GA). Argon, nitrogen, oxygen, and
nitric oxide calibration gas (25.87 ppm in nitrogen) were
purchased from Airgas National Welders (Raleigh, NC). Nitric
oxide gas was purchased from Praxair (Danbury, CT). Water
was purified using a Millipore Milli-Q UV gradient A10 system
(Bedford, MA) to a resistivity of 18.2 MΩ·cm and a total
organic content of ≤6 ppb. All other chemicals were reagent
grade and used as received.
Synthesis of NO-Releasing Silica Nanoparticles. Syn-
thesis of NO-releasing silica nanoparticles was carried out as
described previously.28 Briefly, MPTMS particles were
synthesized via the co-condensation of MPTMS (70 mol %)
and TEOS. The thiol-containing nanoparticles were nitrosated
by reaction with acidified nitrite in the dark at 0 °C for 2 h.
Mesoporous MAP3 silica nanoparticles were prepared via the
surfactant-templated co-condensation of TEOS in the presence
of CTAB, followed by removal of CTAB and surface-grafting of
MAP3 to the particle surface. Subsequent N-diazeniumdiolation
of the secondary amine-containing nanoparticles was carried
out under high pressures of NO (10 atm) at room temperature
for 3 d in the presence of sodium methoxide. Sizes and total
NO-release payloads of the silica nanoparticles are included in
the Supporting Information [SI] (Table S2).
Preparation of NO-Releasing Mock Sensors. Steel wire
was cut in 7 cm pieces and cleaned by sonication in EtOH for
10 min. Polymer solutions containing the macromolecular NO-
release scaffolds were prepared by dispersing MAP3 or
MPTMS particles (72 and 48 mg mL−1, respectively) in an
80 mg mL−1 solution of 50:50 wt % HPU/TPU in 1:1 EtOH/
THF. Wire substrates were modified by dip coating (5 mm s−1
with a 5-s hold time) four times into the particle-containing PU
solution using a DipMaster 50 dip coater (Chemat Technology,
Inc.; Northridge, CA) with 30 min drying periods under
ambient conditions between dips. A final TPU topcoat was
applied by dip coating into a 40 mg mL−1 TPU solution in
THF.
Characterization of NO-Releasing Wire Substrates.
Nitric oxide release from steel wire substrates was measured in
real time using a Sievers 280i chemiluminescence NO analyzer
(NOA; Boulder, CO). Generation of NO from PU films was
detected indirectly by the formation of a chemiluminescent
product (NO2*) upon reaction of NO with ozone. The NOA
was calibrated using an atmospheric gas sample passed through
a Sievers NO zero filter (0 ppb) and 25.9 ppm of NO in N2.
Substrates were immersed in deoxygenated phosphate buffered
saline (PBS; 0.01 M, pH 7.4) at 37 °C. The liberated NO from
PU films was carried to the NOA by a stream of N2, bubbled
into solution at a volumetric flow rate of 75 mL min−1. For
films containing S-nitrosothiol NO donors (i.e., MPTMS
particles), the sample flask was shielded from light, and 500
μM DTPA was added to the PBS buffer to chelate trace copper.
Data output from the NOA was collected every 1 s, allowing for
near real-time monitoring of NO generated from the films.
The stability of silica particles in PU films was assessed using
inductively coupled plasma optical emission spectrometry
(ICP-OES). Modified wire substrates were immersed in PBS
buffer and incubated at 37 °C for 10 d. The degree of particle
leaching into soak solutions was determined by monitoring the
silicon emission intensity at 251.611 nm using a Prodigy high
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dispersion ICP (Teledyne Leeman Laboratories; Hudson,
NH).
Fabrication and Benchtop Performance of NO-
Releasing Needle-Type Glucose Sensors. Bare needle-
type glucose sensors (Pinnacle Technology, Inc., Lawrence,
KS), composed of an integrated silver/silver chloride (Ag/
AgCl) pseudoreference electrode wound around a 90:10
platinum/iridium (Pt/Ir) working electrode (127 μm diam,
∼1 mm length), were functionalized by the successive
deposition of a polyphenol selectivity layer, a GOx enzyme
layer, a NO-releasing flux-limiting membrane, and a polyur-
ethane topcoat, as described previously.29−31 Experimental
details regarding biosensor sterilization, functionalization, and
benchtop testing are provided in the SI. Following deposition
of the selectivity and enzyme layers, sensors were coated with a
PU diffusion-limiting/NO-releasing layer by dip-coating into a
particle-containing PU solution. A TPU topcoat was then
applied as an additional layer. Control sensors were coated
using PU solutions containing MAP3 or MPTMS nanoparticles
(72 and 48 mg mL−1, respectively) that were not functionalized
with N-diazeniumdiolate or S-nitrosothiol NO donors.
In Vivo Protocol for Assessing Biosensor Analytical
Performance. The animal protocol used in this study was
approved by the IACUC at Synchrony, LLC (Durham, NC).
The in vivo performance of glucose biosensors was evaluated in
Yorkshire-type piglets (n = 10; Palmetto Research Swine;
Reevesville, SC) weighing approximately 7−15 kg. Details
regarding sensor implantation and operation are provided in
the SI. Biosensor performance was evaluated on 0, 1, 3, 7, and
10 d after sensor implantation. A peripherally inserted central
catheter was placed in an external jugular vein for blood draws.
Reference blood glucose (BG) concentrations were measured
every 10 min for 6−8 h using a One Touch Ultra glucometer
(LifeScan, Inc.; Milpitas, CA) for comparison to sensor data.
During glucose sensor evaluation, pigs were fasted and sedated
with propofol (2 mg kg−1 h−1) administered through a catheter
in a peripheral ear vein. Once on the day of implantation and
three times daily thereafter, the swine were challenged with an
intravenous glucose tolerance test (IVGTT; 0.7 g kg−1, 50 wt %
dextrose, 1−1.5 h duration), administered over 30 s through
the peripheral catheter, to assess the ability of glucose sensors
to track changing blood glucose concentrations. On day 10,
pigs were euthanized and the sensors were explanted by
removal of the surrounding tissue en bloc. Postexplantation,
sensors were imaged using environmental scanning electron
microscopy (ESEM; FEI Quanta 200 Field Emission Gun;
Hillsboro, OR).
Data Analysis. Sensor current traces were filtered and
analyzed using custom MATLAB scripts (Mathworks, Inc.;
Natick, MA). A finite impulse response (FIR) filter was used to
attenuate large noise spikes caused by pig motion and
potentiostat RF transmitter dropout.32 A 1 min median filter
was used to further smooth the data before pairing sensor
current traces with reference measurements. Glucose sensors
were calibrated with respect to reference BG measurements
once per day using a two-point retrospective calibration.33,34
One point for calibration was taken at a stable glucose baseline
(i.e., prior to the first IVGTT), while the second point was
taken at a stable point after the first dextrose administration
with at least a 15 mg dL−1 difference between BG
concentrations. The slope of a linear trend line connecting
these two points was taken as the apparent in vivo biosensor
sensitivity on each day, expressed as mean values ± standard
deviation. The method of Poincare ́ was used to approximate
the time delay at which the correlation between the reference
and calibrated sensor signals was greatest, using R2 as the
agreement criterion.35,36 This delay was determined at ∼5 min
and used to correct sensor data on each day for the
physiological time lag that characterizes mass transfer of
glucose from blood to tissue.37 After sensor implantation, the
“run-in” time (i.e., the time required for sensors to achieve a
stable background current) was estimated by determining the
period over which two consecutive sensor measurements
agreed with their respective reference measurements within
20%.
Sensor performance was determined using numerical and
clinical accuracy metrics. The mean absolute relative deviation
(MARD) for a data set collected by a single sensor (∼25−35
measurements) was used to characterize sensor numerical
accuracy at each time point.38 Sensor MARD was calculated
using eq 1, where CGM and BG are the blood glucose values
determined by the sensor and reference glucometer,
respectively.









Additionally, the International Standards Organization (ISO)
criteria for glucose monitor performance was used to assess
sensor numerical accuracy by separately calculating the
percentage of glucose measurements determined by sensors
that were within (1) ±15 mg dL−1 of the paired reference
determination when BG was ≤70 mg dL−1 and (2) ±20% of
the paired reference determination when BG was >70 mg
dL−1.38 Sensor clinical accuracy was determined using Clarke
error grid analysis (EGA) by quantifying the percentage of
blood glucose determinations falling in zones A and B of the
error grid.39 Cross-correlation of the reference signals and raw
sensor current traces was used to estimate sensor lag time, with
possible lag times restricted to >100 s.40,41 Values for MARD
and lag time are expressed as mean values ± standard error of
the mean. Differences in median values for sensor MARD, lag
time, and sensitivity between NO-releasing and control sensors
were analyzed using a two-tailed nonparametric Mann−
Whitney U test.42
■ RESULTS AND DISCUSSION
Nitric oxide-releasing polyurethanes were selected as sensor
coatings for evaluating the effect of NO-release duration on in
vivo glucose biosensor performance. Total NO payloads
sufficient for minimizing inflammation (i.e., >1 μmol cm−2)23
with varied NO-release durations (<1 h to >14 d) were
achieved by tuning the PU properties (i.e., water uptake) and
NO donor type.30 We have shown previously that sensor
response is not negatively affected by NO release from PU
coatings at a working electrode potential of +600 mV vs Ag/
AgCl.30 The versatile NO-release kinetics and compatibility
with amperometric glucose sensing make NO-releasing polyur-
ethanes an ideal platform for assessing the effects of NO release
on in vivo glucose biosensor performance.
In Vitro Characterization of NO-Releasing Glucose
Sensors. Wire substrates, selected to mimic the geometry and
size of a needle-type glucose sensor, were modified with NO-
releasing PU coatings via a dip-coating procedure. A hydro-
phobic TPU topcoat was employed to both minimize any
leaching of the macromolecular NO donors and eliminate the
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surface roughness introduced by nanoparticle dopants.
Undoubtedly, the physical properties (i.e., roughness) of an
implant surface will affect the FBR.15,43 The stability of the
nanoparticle-doped PU coatings in PBS was investigated over
10 d by analyzing the silicon content of soak solutions using
ICP-OES. While silica is intrinsically biocompatible and
considered nontoxic,23,44 the resulting changes in coating
structure or potential tissue inflammation may affect the
performance of glucose sensors in vivo. For coatings doped
with NO-releasing MPTMS-RSNO particles as well as controls,
leaching of silica particles from the PU matrix was undetectable
(<2%). Slight leaching (10.8 ± 2.9% of the total incorporated
silica) was observed from coatings containing NO-releasing
MAP3/NO particles. Interestingly, the majority of the observed
leaching occurred during the first 4 h, suggesting some
instability associated with encapsulating the charged N-
diazeniumdiolate NO donor moieties within the polyurethane
coating (data not shown).
The effect of NO-release duration on in vivo sensor
performance was studied using two different macromolecular
NO release systems: N-diazeniumdiolate NO donors and S-
nitrosothiol-modified silica nanoparticles (MAP3/NO and
MPTMS-RSNO, respectively). Briefly, N-diazeniumdiolate
NO donors undergo proton-initiated decomposition in
aqueous milieu to generate NO.45 Conversely, NO release
from S-nitrosothiols may be triggered using light or Cu(I), but
S-nitrosothiols also decompose sluggishly through thermal
mechanisms in vivo.28,46 To simulate in vivo conditions, NO
release from PU films was measured in PBS at 37 °C. For
MPTMS-RSNO coatings, thermal decomposition of the S-
nitrosothiol moieties was achieved using a light-shielded sample
flask and the addition of DTPA to chelate trace copper. By
appropriate selection of the nanoparticle dopant concentration
(72 and 48 mg mL−1 for MAP3/NO and MPTMS-RSNO
particles, respectively) we attained similar total NO payloads
(∼3.1 μmol cm−2) for both coating formulations (Table 1). Of
note, NO payloads from these coatings were more than 2 times
greater than that from the xerogel coatings utilized by Hetrick
et al. (∼1.35 μmol cm−2) and similar in magnitude to those
employed by Nichols et al. (2.7−9.3 μmol cm−2)both of
which proved effective at reducing the FBR to subcutaneous
implants.23,25
Upon immersion in PBS, MAP3/NO films exhibited a large
initial NO flux ([NO]max = 685.8 ± 11.4 pmol cm
−2 s−1) and
released 99% of their total NO payload within ∼16 h, with no
additional NO release measurable beyond 24 h. Such duration
(16 h) was similar to that reported to improve glucose sensor
accuracy by Gifford and co-workers (12−18 h).26 Similarly,
MPTMS-RSNO films showed a large initial NO flux ([NO]max
= 551.4 ± 130.0 pmol cm−2 s−1), with a rapid decrease to ∼14.0
pmol cm−2 s−1 at 8 h. In contrast to the MAP3/NO films,
MPTMS-RSNO coatings required ∼3.1 d to release 99% of
their total NO payload, with NO release (0.5 pmol cm−2 s−1)
still measurable at ∼7 d. Even such low levels of NO are
physiologically relevant, as vascular endothelial cells release NO
at 1−7 pmol cm−2 s−1 to prevent platelet activation.27,47
Additionally, similar NO fluxes (1.5−30 pmol cm−2 s−1) inhibit
in vitro bacterial adhesion to surfaces.48,49
As expected, NO release from the outer glucose sensor
membrane did not impact biosensor response. After an initial
hydration period of 3−4 h, the glucose sensitivities of NO-
releasing and control sensors were comparable and remained
constant (1.3−2.3 nA mM−1) over 10 d in PBS at 37 °C for all
membrane formulations. In the absence of preconditioning,
sensors exhibited poorer dynamic range and longer response
times to changes in glucose concentration during the first
several hours of testing (data not shown). Both NO-releasing
and control sensors exhibited acceptable response times (<40
s) to an increase in glucose concentration of 5.6 mM. All
sensors responded linearly to glucose between 1−12 mM after
preconditioning in PBS. Furthermore, the amperometric
selectivity coefficients for glucose over acetaminophen, ascorbic
acid, and urea were 0.82 ± 0.30, 0.49 ± 0.11, and 0.03 ± 0.01,
respectively, for blank sensors (i.e., sensors that were coated
solely with polyurethane). As expected, selectivity for glucose
was sufficient. The analytical performance merits of the sensors
are provided in the SI (Table S1).
In Vivo Biosensor Run-In Time, Glucose Sensitivity,
and Clarke Error Grid. Following implantation, both NO-
releasing and control biosensors displayed a run-in period (i.e.,
the time required to achieve a stable baseline current) during
which the sensor response was erratic (Figure S3 in the SI).
While Gifford et al. reported a reduced run-in time for NO-
releasing sensors versus control sensors in rodents,26 we
observed no significant differences in run-in time between NO-
releasing sensors and controls, with all four sensor config-
urations requiring ∼3−6 h to achieve a steady background
current. The source of this discrepancy is unclear, but a number
of variables (e.g., different animal model, implant method, and
extended sensor hydration time) may have contributed to this
result.
The potential analytical performance benefits of NO-
releasing amperometric glucose biosensors were evaluated in
a healthy swine model. The use of digital noise filters was
required to achieve stable current traces due to swine motion
and intermittent potentiostat RF transmitter dropout. The
filtering algorithms were restricted to those compatible with
real-time continuous glucose monitoring.32 As expected, the
FIR and median filters sufficiently improved signal quality
without introducing an undesirable artificial time delay (>20%)
between sensor and reference signals. Subsequently, sensors
were calibrated by comparison to corresponding reference
blood glucose measurements using a two-point retrospective
Table 1. Nitric Oxide Release from Polyurethane Coatings
Doped with NO-Releasing MPTMS-RSNO and MAP3/NO
Nanoparticles
NO-release merits MPTMS-RSNO MAP3/NO
[NO]max (pmol cm
−2 s−1) 551.4 ± 130.0 685.8 ± 11.4
tmax (min)
a 1.68 ± 0.20 23.80 ± 7.17
t1/2 (h)
b 6.29 ± 2.07 0.93 ± 0.17
[NO]8h (pmol cm
−2 s−1) 14.0 ± 3.9 13.0 ± 3.2
[NO]12h (pmol cm
−2 s−1) 9.8 ± 3.8 3.7 ± 1.5
[NO]24h (pmol cm
−2 s−1) 3.3 ± 0.2 0c
[NO]48h (pmol cm
−2 s−1) 1.0 ± 0.1 0c
[NO]72h (pmol cm
−2 s−1) 0.5 ± 0.0 0c
[NO]168h (pmol cm
−2 s−1) 0.5 ± 0.0 0c
[NO]T (μmol cm
−2)d 3.14 ± 0.26e 3.11 ± 0.27
td (h)
f 74.6 ± 16.6 16.0 ± 4.4
aTime required to reach maximum NO flux. bHalf-life for NO-release
from PU films. cNitric oxide release was below the limit of detection of
the NOA. dTotal amount of NO released. eMeasured by irradiation of
the sample flask with 200 W light. fDetermined at the time at which
99% of the total NO was released.
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calibration. While a one-point calibration (which assumes a
negligible background current) has been suggested to be
superior to the two-point calibration,33,34 the in vivo back-
ground in our study was substantial (6−10 nA) compared to
the in vitro baseline (1−3 nA), necessitating the use of a two-
point calibration. Other researchers have also reported
disparities between in vitro and in vivo sensor baseline
currents.50 Despite minimizing the artificial delay caused by
filtering, a physiological lag between the sensor signal and
reference BG measurements was still observed. This delay
arises from the slow mass transfer of glucose from the
vasculature to the tissue and ultimately the sensor.35−37 An
analysis of sensor performance on day 0 via the method of
Poincare ́36 indicated a ∼5 min lag between the reference signal
and calibrated sensor signal. This lag time was thus accounted
for in all remaining data sets (days 1, 3, 7, and 10) by shifting
the reference signal in time relative to the sensor signal.
The clinical accuracies of NO-releasing and control in vivo
glucose biosensors were first assessed via the Clarke error
grid.39 The percentage of BG measurements falling in zones A
and B (clinically accurate and clinically benign determinations,
respectively) of the error grid are shown in Table 2. On the day
of implantation (day 0), the MAP3/NO-based sensors
performed slightly worse than control sensors, with a 2%
difference in the percentage of determinations in zones A and
B. However, the performance of MAP3/NO sensors on days 1
and 3 was superior to that of controls, with >7% difference in
the percentage of clinically accurate and acceptable determi-
nations. Concomitant with improved clinical performance,
sensors that rapidly released NO were characterized as having
greater glucose sensitivity on days 1 and 3 (0.59 ± 0.54 and
0.59 ± 0.40 nA mM−1, respectively) versus controls (0.14 ±
0.09 and 0.18 ± 0.04 nA mM−1, respectively). However, the
MAP3/NO sensors exhibited similar clinical accuracy and
glucose sensitivity to control sensors at implant periods beyond
3 days (i.e., days 7 and 10), suggesting that sensor performance
is only improved during periods of active NO release. The
trends in sensor clinical performance and glucose sensitivity
correlate well with the NO-release kinetics from the sensors,
with clear benefits to sensor performance early during in vivo
use (i.e., days 1 and 3) but no improvements after the NO
supply was exhausted. Of note, Nichols et al. noted no decrease
in the FBR (>1 w) for implants with rapid NO release,
suggesting that inflammation may be the primary culprit for
Table 2. Clinical Performance and Apparent in Vivo Sensitivity of Glucose Biosensors
day MAP3 control MAP3/NO MPTMS control MPTMS-RSNO
0 % points in zones A/B 89.6 87.6 91.0 94.7
Na 183 105 311 321
sensitivity (nA mM−1) 0.90 ± 0.87 0.72 ± 0.40 0.74 ± 0.47 0.60 ± 0.30
1 % points in zones A/B 78.6 86.2 90.6 89.1
Na 168 174 224 347
sensitivity (nA mM−1) 0.14 ± 0.09 0.59 ± 0.54b 0.29 ± 0.18 0.39 ± 0.17
3 % points in zones A/B 84.8 92.0 81.7 83.9
Na 169 173 180 124
sensitivity (nA mM−1) 0.18 ± 0.04 0.59 ± 0.40b 0.24 ± 0.16 0.49 ± 0.18
7 % points in zones A/B 93.2 94.2 88.3 88.1
Na 115 87 157 69
sensitivity (nA mM−1) 0.23 ± 0.15 0.39 ± 0.26 0.20 ± 0.07 0.45 ± 0.19
10 % points in zones A/B 84.8 81.4 91.8 84.9
Na 138 97 135 66
sensitivity (nA mM−1) 0.16 ± 0.06 0.20 ± 0.13 0.09 ± 0.02 1.3 ± 1.1
aTotal number of measurements. bSignificantly different at p < 0.05.
Figure 1. Comparison of MARD for (A) MAP3/NO (red circle) and control (MAP3) sensors (black, square) and (B) MPTMS-RSNO (red circle)
and control (MPTMS) (black, square) sensors. Significant differences (p < 0.05) in the median value for the MARD are indicated with an asterisk.
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decreased sensor performance beyond 3 d.25 Unexpectedly, the
MPTMS-RSNO-based sensors exhibited clinical accuracy
similar to that of MPTMS control sensors throughout the 10
d in vivo study. The sensitivity of the MPTMS-RSNO sensors
to glucose appeared slightly greater than that of MPTMS
controls beyond day 0, but these differences were not
significant (p > 0.05). This result may be due to the low,
sustained NO fluxes released from sensors when compared to
those from the MAP3/NO-based sensors (Table 1).
Of importance, the majority (∼70%) of BG determinations
were obtained in the 50−100 mg dL−1 range, as shown in the
representative Clarke error grid analysis in Figure S4 of the SI.
In addition to the similarities between swine and humans (e.g.,
skin, vasculature, subcutaneous tissue composition) which
render the pig an appropriate model for evaluating in vivo
biosensors, baseline blood glucose concentrations obtained in
this study were comparable to human euglycemic levels.26,50−52
As maintenance of euglycemia increases the propensity of
diabetic individuals to enter the hypoglycemic BG range,53 the
Clarke error grid presents austere requirements for sensor
accuracy in this region. Thus, the error grid analysis presented
herein is at BG levels clinically and physiologically pertinent to
humans.
Biosensor Numerical Accuracy and Adherence to ISO
Criteria. To evaluate in vivo biosensor performance in more
detail, the sensor numerical accuracy was represented using the
MARD of each sensor from corresponding reference values.38
While the Clarke error grid measures sensor accuracy based on
the clinical implications of a given BG measurement, the
MARD represents a statistical entity that exemplifies the
average percent deviation of the sensor from a reference.
Additionally, ISO criteria for in vivo glucose biosensor
performance was considered as a metric for numerical accuracy
because it can be used to assess sensor accuracy in both
hypoglycemic (≤70 mg dL−1) and euglycemic/hyperglycemic
(>70 mg dL−1) BG ranges separately.38 A comparison of the
numerical accuracies for control and NO-releasing sensors is
shown in Figure 1. As anticipated, the analytical performance of
MAP3/NO-based sensors on days 1 and 3 was superior to that
of MAP3 (control) sensors. The improvements in numerical
accuracy agree with the increased clinical accuracy and greater
glucose sensitivity for the more rapid NO-releasing sensors.
Furthermore, the performance of the MAP3/NO-based sensors
was observed to worsen beyond 3 d implantation. The desirably
lower MARD for rapid NO-releasing glucose sensors is
attributed to the improved accuracy in both the hypoglycemic
and euglycemic/hyperglycemic ranges, as shown in Table 3.
Indeed, >55% of the total BG determinations obtained by
MAP3/NO-based sensors agreed well with corresponding
reference measurements in both BG ranges on days 1 and 3.
Unexpectedly, the MARD for control (MAP3) sensors was
lowest at 7 d implantation (21.9 ± 13.1%). Despite the
inconsistent numerical accuracy for control sensors, the
analytical performance was comparable to NO-releasing sensors
at both 7 and 10 d.
Although the clinical accuracy of the MPTMS-RSNO-based
sensors was comparable to that of controls, the numerical
accuracy of NO-releasing sensors remained constant (MARD
range 22.2−26.0%) throughout the experiment. Furthermore,
the sensors that released NO for extended durations exhibited a
significantly lower MARD on days 1 and 3 (26.0 ± 5.1 and 23.9
± 8.6%, respectively) versus controls (34.3 ± 10.9 and 38.8 ±
10.4%, respectively). We attribute the good agreement between
MPTMS-RSNO sensors and reference measurements to the
increased accuracy of the NO-releasing biosensors in both the
hypoglycemic and euglycemic/hyperglycemic BG ranges. The
percentage of determinations for MPTMS-RSNO-based
sensors that adhered to ISO criteria was typically >50%
throughout implantation, while control sensor performance
worsened with implant duration, particularly in the hypo-
glycemic range. The stable biosensor response provided by the
sustained NO-releasing sensor membranes highlights the utility
of NO release for continuous glucose monitoring.
Of importance, the NO-release kinetics also correlated with
the magnitude of the improvement in numerical accuracy for
NO-releasing sensors versus controls. For example, MAP3/
NO-based sensors showed vastly decreased MARD versus
MAP3 (control) sensors on day 1 (22.0 ± 6.6 and 47.3 ± 8.1%,
respectively), whereas sensors with longer NO-release
durations (MPTMS-RSNO) exhibited more modest improve-
ments relative to controls (28.4 ± 5.9 and 34.3 ± 10.9%,
respectively). However, the differences in the MARD between
MAP3/NO and MPTMS-RSNO sensors on days 1 and 3 were
not statistically significant (p > 0.05). The enhanced numerical
accuracy afforded by rapid NO release from sensor membranes
indicates a possible advantage to greater NO fluxes, as MAP3/
NO-based sensors delivered ∼3.1 μmol cm−2 NO in <24 h.
While MPTMS-RSNO sensors had a near constant MARD
throughout the experiment duration, the improvements in
numerical accuracy provided by lower, more sustained NO
release may not have been large enough to result in improved
clinical performance. Collectively, these results suggest that
sensor performance benefits to a greater extent with prolonged
NO release and that these gains are dependent on the fluxes at
which NO is liberated.
Biosensor Lag Time. While poor glucose sensitivity often
contributes to undesirable sensor performance in vivo,
diminished accuracy also results from sluggish response of
the sensor to changes in BG levels.54 In addition to an inherent
blood−tissue glucose lag, progression of the FBR increases the
difficulty of glucose diffusion to the sensor. Distinct properties
of the collagen capsule (i.e., thickness, density, and avascularity)
produced upon resolution of the foreign body response have
been shown to affect the transport properties of small
molecules in the subcutaneous tissue.12−14 Even in the absence
of a mature fibrotic capsule, biofouling and inflammation at the
sensor−tissue interface may create a diffusion barrier to
glucose.55 As amperometric glucose biosensors are diffusion-
limited with respect to glucose, a longer response time may
hinder the competence of the sensor to track rapid changes in
BG levels, resulting in decreased accuracy. Since tissue
surrounding NO-releasing implants exhibits less inflamma-










0 58.0a/50.0b 51.9/61.5 55.7/60.0 60.2/67.0
1 37.9/39.2 55.6/56.7 45.9/59.7 55.5/59.4
3 52.9/47.7 65.6/57.3 39.5/57.3 58.5/74.7
7 62.5/62.7 42.1/57.8 35.5/45.2 42.1/52.0
10 55.6/54.9 30.6/45.9 15.0/34.8 63.6/45.5
aCalculated as the percentage of determinations within 15 mg dL−1 of
the reference measurement when BG ≤ 70 mg dL−1 bCalculated as the
percentage of determinations within 20% of the reference measure-
ment when BG > 70 mg dL−1
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tion,23−25 reduced collagen encapsulation,23,25 and low
impedance to glucose transport,24 NO-releasing sensors may
show more rapid response to changes in BG. While time-
shifting methods (i.e., Poincare ́ dynamical analysis) have been
used to correct CGM data for time-lag effects,35,36 calibration of
the sensor signal may corrupt a comparison of sensor lag times.
Cross-correlation of the raw sensor signals and paired reference
signals were thus used to estimate sensor delay, avoiding the
requirement for sensor calibration.40,41
Initially (i.e., 0−1 d implant period), NO release had little
effect on sensor lag times (Figure 2). However, NO release did
impact sensor lag times on days 3, 7, and 10. The MPTMS-
RSNO-based sensors yielded a faster response to changing
glucose concentrations during the IVGTT (<4.2 min)
compared with both control (MPTMS) and MAP3/NO-
based sensors (>5.8 min). As well, the response time of the
MAP3/NO-based sensors worsened with implantation time
analogous to control sensors, suggesting that the benefit of
reduced response time is only attained when sensors are still
releasing NO. Despite similar NO payloads, the difference in
lag time between the two types of NO-releasing sensors is
corroborated by the work of Nichols et al.,25 in which rapid NO
release at 3 and 7 d yielded no reduction in FBR, while
extended NO release provided a lessened FBR at both 3 and 7
d. Likewise, sustained NO release from percutaneously
implanted microdialysis probes reduced tissue impedance to
glucose transport,24 which may explain the reduced sensor lag
time observed in the present study.
Postexplantation Analysis. Approximately 40% of
implanted NO-releasing and control sensors functioned beyond
3 d, indicating a limitation in this study. Following sensor
explantation, the sensors were imaged via environmental
scanning electron microscopy to investigate the implant
surfaces and perhaps understand the potential sources of
sensor failure. Representative scanning electron micrographs
(SEMs) of the surface of the sensors are provided in SI (Figure
S5). Electrical failure via membrane delamination or cracking
contributed considerably to in vivo sensor failure. Most likely,
mechanical stresses to the percutaneous sensor were at fault for
damage to the sensor membranes.50 Koschwanez et al.
previously reported that micromotion and the associated stress
for percutaneous implants yielded unanticipated results for
studies evaluating glucose sensor coatings.56 Indeed, the
significant mechanical stress to percutaneous implants con-
volutes the interpretation of sensor failure. Nonetheless,
percutaneous glucose sensors remain the most realistic method
for implementing continuous glucose monitoring, due to their
low cost and facile implantation, and serve as a suitable model
for evaluating candidate biomaterials.50,57 Furthermore, NO has
been shown to provide benefits to percutaneous implants even
in the presence of such physical factors.24
■ CONCLUSIONS
Nitric oxide was shown to clearly enhance the analytical
performance of in vivo glucose biosensors with the associated
benefits being dependent on the NO-release kinetics from the
outer sensor membranes. Both rapid and extended NO-
releasing sensors exhibited improved numerical accuracy versus
controls. Rapid NO release from sensors resulted in positive
differences in both clinical accuracy and glucose sensitivity,
while sustained NO release from MPTMS-RSNO biosensors
provided constant numerical accuracy over the entire 10 d
implant period. The MPTMS-RSNO sensors were charac-
terized by a quicker response to the IVGTT than both the
MPTMS control and MAP3-based sensors, which we attribute
to the sustained generation of NO. It is hypothesized that
shorter lag times for the MPTMS-RSNO sensors are the result
of improved glucose transport to the sensor from the tissue
surrounding the implants. The predictable performance of
MPTMS-RSNO glucose biosensors suggests that materials that
are capable of releasing large NO payloads for even longer
durations (i.e., several weeks) represent the ultimate NO-
release strategy for long-term glucose sensing technologies (i.e.,
months), rather than the short-term (i.e., ∼10 d) period that
was the focus of this study. However, the effects of NO on
diabetic tissue may be dissimilar. Indeed, diabetic tissue is
characterized by numerous deficiencies including altered wound
repair,58,59 lessened inflammation and pro-inflammatory
cytokine production at wound sites,59 disrupted blood flow,60
and susceptibility to infection.61 Work characterizing the
response of diabetic tissue to implantation has been limited
thus far. The disparities between diabetic and healthy tissue
motivate the need for understanding the diabetic response to
sensor implantation and warrant a careful investigation of the
role of NO on the diabetic FBR. Planning of these studies in a
diabetic swine model is ongoing.
■ ASSOCIATED CONTENT
*S Supporting Information
Real-time NO-release profiles of glucose sensor outer
membranes, glucose sensor sensitivity as a function of storage
time in PBS, nanoparticle characterization, representative EGA,
sensor run-in times, experimental protocols, and representative
SEMs of sensor surfaces postexplantation. This material is
available free of charge via the Internet at http://pubs.acs.org.
Figure 2. Estimation of sensor lag time via cross-correlation. MPTMS-
RSNO biosensors (blue inverted triangle) exhibited significantly
reduced lag times on days 3, 7, and 10 versus MAP3/NO sensors (red
circle), and MAP3 and MPTMS controls (black square and green
triangle, respectively). Asterisks denote significant differences (p <
0.05) in the median values for lag time between the MPTMS-RSNO
sensors and all other sensor types.
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